NCT07014592 Characterization and Analysis of Evoked Cortical Responses in Participants With Medication-intractable Epilepsy
| NCT ID | NCT07014592 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Michigan |
| Condition | Intractable Epilepsy |
| Study Type | INTERVENTIONAL |
| Enrollment | 5 participants |
| Start Date | 2025-05-05 |
| Primary Completion | 2028-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 5 participants in total. It began in 2025-05-05 with a primary completion date of 2028-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this project is to study how the brain reacts to a small electrical signal. Researchers will be using a novel combination of recording electrodes. The researchers will measure the brain response from these electrodes.
Eligibility Criteria
Inclusion Criteria: * Patients with medication intractable epilepsy who are recommended to undergo brain surgery to remove a "seizure" focus * Can provide informed consent for the study and willing to participate Exclusion Criteria: * Presence of a permanent electronic implant * Any chronic medical conditions that prevent safe placement of electrodes
Contact & Investigator
Matthew Willsey, MD, PhD
PRINCIPAL INVESTIGATOR
University of Michigan
Frequently Asked Questions
Who can join the NCT07014592 clinical trial?
This trial is open to participants of all sexes, aged 22 Years or older, up to 75 Years, studying Intractable Epilepsy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07014592 currently recruiting?
Yes, NCT07014592 is actively recruiting participants. Contact the research team at rmball@umich.edu for enrollment information.
Where is the NCT07014592 trial being conducted?
This trial is being conducted at Ann Arbor, United States.
Who is sponsoring the NCT07014592 clinical trial?
NCT07014592 is sponsored by University of Michigan. The principal investigator is Matthew Willsey, MD, PhD at University of Michigan. The trial plans to enroll 5 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.